Follow
Aditi Qamra
Aditi Qamra
Hoffmann-La Roche Canada
Verified email at roche.com
Title
Cited by
Cited by
Year
ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer
THM Chan, A Qamra, KT Tan, J Guo, H Yang, L Qi, JS Lin, VHE Ng, ...
Gastroenterology 151 (4), 637-650. e10, 2016
1542016
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ...
Cancer discovery 7 (11), 1284-1305, 2017
1302017
Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity
WF Ooi, M Xing, C Xu, X Yao, MK Ramlee, MC Lim, F Cao, K Lim, D Babu, ...
Nature communications 7 (1), 12983, 2016
1282016
Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements
M Muratani, N Deng, WF Ooi, SJ Lin, M Xing, C Xu, A Qamra, ST Tay, ...
Nature communications 5 (1), 4361, 2014
822014
Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma
A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ...
Cancer discovery 7 (6), 630-651, 2017
502017
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
R Sundar, KK Huang, A Qamra, KM Kim, ST Kim, WK Kang, ALK Tan, ...
Annals of Oncology 30 (3), 424-430, 2019
492019
HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis
TD Yan, WF Ooi, A Qamra, A Cheung, DL Ma, GM Sundaram, C Xu, ...
Nature communications 9 (1), 100, 2018
472018
HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer
C Xu, WF Ooi, A Qamra, J Tan, BYJ Chua, SWT Ho, K Das, ZFA Isa, Z Li, ...
Gut 69 (2), 231-242, 2020
322020
Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes
R Sundar, A Qamra, ALK Tan, S Zhang, CCY Ng, BT Teh, J Lee, KM Kim, ...
Gastric Cancer 21, 1064-1070, 2018
282018
Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial
J Tom, M Bao, L Tsai, A Qamra, D Summers, M Carrasco-Triguero, ...
Critical Care Medicine 50 (3), 398-409, 2022
272022
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
R Sundar, KK Huang, V Kumar, K Ramnarayanan, D Demircioglu, Z Her, ...
Gut 71 (7), 1277-1288, 2022
242022
Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer
M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ...
The Journal of clinical investigation 130 (6), 3005-3020, 2020
152020
Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma. Cancer Discov. 2017; 7: 630–651. doi: 10.1158/2159-8290
A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ...
CD-16-1022.[Abstract][CrossRef][Google Scholar], 0
15
CRISPRi enables isoform-specific loss-of-function screens and identification of gastric cancer-specific isoform dependencies
R Davies, L Liu, S Taotao, N Tuano, R Chaturvedi, KK Huang, C Itman, ...
Genome biology 22, 1-19, 2021
142021
VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7: 1284–1305. doi: 10.1158/2159-8290
X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ...
CD-17-0375.[Abstract][CrossRef][Google Scholar], 0
14
Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment
M Criqui, A Qamra, TW Chu, M Sharma, J Tsao, DA Henry, ...
Elife 9, e47333, 2020
122020
VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7 (11): 1284-1305. doi: 10.1158/2159-8290
X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ...
CD-17-0375.[Abstract][CrossRef][Google Scholar], 0
7
Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis …
F André, R Deurloo, A Qamra, D Cameron, J Gligorov, A Schneeweiss, ...
Cancer Research 82 (4_Supplement), PD10-05-PD10-05, 2022
62022
Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer
S Cameron, G Deblois, JR Hawley, A Qamra, S Zhou, SAM Tonekaboni, ...
Oncogene 42 (21), 1693-1703, 2023
52023
Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trial
J Tom, M Bao, L Tsai, A Qamra, D Summers, M Carrasco-Triguero, ...
medRxiv, 2020.12. 23.20247379, 2020
52020
The system can't perform the operation now. Try again later.
Articles 1–20